Lumosa's LT3001, a novel therapy for acute ischemic stroke (AIS), has received clearance from Taiwan's Food and Drug Administration (TFDA) to proceed with a Phase 2 exploratory clinical study of LT3001. The approval allows Lumosa to initiate a multi-dose, open-label, single-arm trial designed to examine intracranial arterial recanalization in AIS patients. The study is expected to enroll 10 evaluable participants and will assess recanalization rates 24 hours after the administration of LT3001, The trial is intended to explore the drug's mechanism of action and to inform the design of later0stage development, including Phase 3 studies and eventual regulatory review. 

Acute ischemic stroke accounts for roughly 80% of the estimated 15 million to 17 million strokes reported worldwide each year. Treatment options remain limited. The only approved drug therapy, tissue plasminogen activator (rt‑PA), carries a risk of bleeding and must be administered within a narrow time window, leaving a large majority of patients untreated. Mechanical thrombectomy offers an alternative for some patients, though outcomes vary.

LT3001 is being developed with the aim of expanding treatment options beyond current constraints, potentially enabling use within 24 hours of stroke onset, either alone or concomitant application with mechanical trhombectomy.